Sinil Pharmaceutical Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 17.46%

Sinil Pharmaceutical Co. Ltd (012790) has an Asset Resilience Ratio of 17.46% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 012790 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩29.67 Billion
≈ $20.11 Million USD Cash + Short-term Investments

Total Assets

₩169.94 Billion
≈ $115.16 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Sinil Pharmaceutical Co. Ltd's Asset Resilience Ratio has changed over time. See 012790 equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Sinil Pharmaceutical Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 012790 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩29.67 Billion 17.46%
Total Liquid Assets ₩29.67 Billion 17.46%

Asset Resilience Insights

  • Good Liquidity Position: Sinil Pharmaceutical Co. Ltd maintains a healthy 17.46% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Sinil Pharmaceutical Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Sinil Pharmaceutical Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Sinil Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Sinil Pharmaceutical Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 20.31% ₩33.69 Billion
≈ $22.83 Million
₩165.86 Billion
≈ $112.40 Million
+4.96pp
2023-12-31 15.35% ₩23.41 Billion
≈ $15.86 Million
₩152.46 Billion
≈ $103.32 Million
-0.97pp
2022-12-31 16.32% ₩23.31 Billion
≈ $15.80 Million
₩142.83 Billion
≈ $96.79 Million
+0.16pp
2021-12-31 16.16% ₩20.84 Billion
≈ $14.12 Million
₩128.97 Billion
≈ $87.40 Million
+4.48pp
2020-12-31 11.68% ₩14.57 Billion
≈ $9.88 Million
₩124.81 Billion
≈ $84.58 Million
+0.17pp
2019-12-31 11.50% ₩13.56 Billion
≈ $9.19 Million
₩117.84 Billion
≈ $79.86 Million
-1.32pp
2018-12-31 12.83% ₩13.65 Billion
≈ $9.25 Million
₩106.40 Billion
≈ $72.11 Million
-0.10pp
2017-12-31 12.93% ₩13.25 Billion
≈ $8.98 Million
₩102.52 Billion
≈ $69.48 Million
-1.86pp
2016-12-31 14.79% ₩14.50 Billion
≈ $9.83 Million
₩98.05 Billion
≈ $66.45 Million
-2.98pp
2015-12-31 17.77% ₩15.51 Billion
≈ $10.51 Million
₩87.26 Billion
≈ $59.14 Million
-0.66pp
2014-12-31 18.43% ₩14.73 Billion
≈ $9.98 Million
₩79.91 Billion
≈ $54.15 Million
--
pp = percentage points

About Sinil Pharmaceutical Co. Ltd

KQ:012790 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$41.99 Million
₩61.96 Billion KRW
Market Cap Rank
#22603 Global
#1445 in Korea
Share Price
₩5360.00
Change (1 day)
-1.11%
52-Week Range
₩5000.00 - ₩6920.00
All Time High
₩50717.45
About

Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more